
Rezolute RZLT
$ 3.24
0.62%
Quarterly report 2026-Q3
added 05-12-2026
Rezolute General and Administrative Expenses 2011-2026 | RZLT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Rezolute
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.4 M | 14.7 M | 12.2 M | 9.36 M | 7.91 M | 6.07 M | 6.82 M | 9.1 M | 8.23 M | 5.5 M | 6 M | 5.13 M | 6.1 M | 42.7 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.4 M | 42.7 K | 8.25 M |
Quarterly General and Administrative Expenses Rezolute
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.95 M | 9.87 M | 6.67 M | 9.87 M | 6.67 M | - | 4.74 M | 4.45 M | 4.19 M | - | 3.81 M | 3.16 M | 3.7 M | - | 2.91 M | 3.45 M | 2.51 M | 5.96 M | 2.07 M | 2.7 M | 1.87 M | 4.56 M | 1.72 M | 2.66 M | 1.28 M | 2.66 M | 1.28 M | 1.68 M | 1.94 M | 1.68 M | 420 K | 292 K | 239 K | 531 K | 414 K | 318 K | 328 K | 318 K | 328 K | 302 K | 257 K | 302 K | 257 K | 198 K | 205 K | 198 K | 205 K | 184 K | 356 K | 184 K | 553 K | 80.5 K | 17.4 K | 7.54 K | 19.5 K | 23.2 K | 5.01 K | 9.31 K | 3.53 K | 8 K | 7.39 K | 8 K | 7.39 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.87 M | 3.53 K | 1.84 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
2.31 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.9 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
10.5 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | ||
|
IMV
IMV
|
17 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
514 M | $ 90.55 | 0.21 % | $ 21.9 B | ||
|
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.65 | 1.54 % | $ 439 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
7.72 M | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
8.89 M | $ 2.6 | -3.88 % | $ 243 M | ||
|
Anika Therapeutics
ANIK
|
49.1 M | $ 15.1 | -0.26 % | $ 217 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
10.1 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.29 | -0.98 % | $ 5.42 M | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
101 M | $ 1.54 | 2.07 % | $ 180 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
38.8 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 20.66 | 0.93 % | $ 2.63 B | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
7.16 M | - | 17.91 % | $ 11.1 M |